GE HealthCare Technologies Inc. (GEHC) Stock Price & Analysis
GE HealthCare Technologies Inc. (GEHC) closed at USD 71.42 on Thursday, October 22, 2026, up 3.49% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 71.42; the Oct 22, 2026 session ranged USD 69.31–71.7 on volume of 3,131,579 shares. Market capitalization is —, with a 52-week range of USD 58.75–89.77 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/GEHC.md
Key facts (GEHC)
- Last four reported quarters (through Jun 30, 2026): revenue $21.3B, net income $1.99B (9.3% margin), free cash flow $1.58B (SEC filings).
- Valuation: P/E 16.3x (avg 19.5x at the last 3 fiscal year-ends), EV/EBITDA 13.3x, net debt $8.01B.
- 8 of 80 tracked superinvestors hold GEHC (13F, Q2 2026): 2 new, 3 added, 2 reduced, 1 unchanged.
- Insider open-market purchases, last ~7 months: 8 Form 4 filings, $6.4M; 0 by opportunistic insiders, 0 by routine insiders.
- Total return with dividends: 1Y -7.4% vs S&P 500 +14.9%; 5Y +26.6% vs S&P 500 +80.3%.
- Next earnings: 2026-10-28, EPS estimate USD 1.2, revenue estimate $5.35B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (GEHC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $17.6B | $18.3B | $19.6B | $19.7B | $20.6B | $21.3B |
| Gross profit | $7.17B | $7.18B | $7.92B | $8.21B | $8.25B | — |
| Operating income | $2.79B | $2.52B | $2.44B | $2.63B | $2.76B | $2.73B |
| Net income | $2.25B | $1.92B | $1.57B | $1.99B | $2.08B | $1.99B |
| EPS (diluted) | $4.95 | $4.22 | $3.03 | $4.34 | $4.55 | — |
| Free cash flow | $1.36B | $1.82B | $1.71B | $1.55B | $1.50B | $1.58B |
| Gross margin | 40.8% | 39.1% | 40.5% | 41.7% | 40.0% | — |
| Operating margin | 15.9% | 13.8% | 12.5% | 13.3% | 13.4% | 12.9% |
| Net margin | 12.8% | 10.4% | 8.0% | 10.1% | 10.1% | 9.3% |
| Revenue growth | — | +4.3% | +6.6% | +0.6% | +4.8% | — |
| Cash + short-term investments | $561M | $1.44B | $2.49B | $2.87B | $4.49B | — |
| Total debt | — | $8.25B | $9.44B | $8.95B | $10.0B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (GEHC)
P/E 16.3x · P/S 1.5x · EV/EBITDA 13.3x · EV/Sales 1.9x · P/FCF 20.4x · P/B 2.9x · FCF yield 4.89% · Earnings yield 6.15% · Dividend yield (paid, TTM) 0.20% · Buyback yield (TTM) 1.24% · Net debt $8.01B · EV $40.3B
P/E at fiscal year-ends: Dec 2025 18.0x, Dec 2024 18.0x, Dec 2023 22.6x.
Superinvestors (SEC 13F-HR, Q2 2026) (GEHC)
8 of 80 tracked investors hold GEHC. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Nelson Peltz | Trian Fund Management | 4.67% | $197M | New position |
| Leon Cooperman | Omega Family Office | 2.36% | $83.8M | Added +95.5% |
| Harry Burn | Sound Shore | 2.21% | $71.6M | Reduced -6.2% |
| Bill Nygren | Oakmark Funds | 1.31% | $981M | Reduced -1.7% |
| Dodge & Cox Funds | Dodge & Cox | 1.27% | $2.42B | Added +20.9% |
| First Pacific Advisors | 0.66% | $53.0M | New position | |
| Christopher Bloomstran | Semper Augustus | 0.03% | $293K | Unchanged |
| First Eagle Investment | First Eagle Investment Management | <0.01% | $16K | Added +347.3% |
Insider purchases (SEC Form 4, open-market, last ~7 months) (GEHC)
8 purchases, $6.4M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-05-22 | Lobo Kevin | Director | 10,000 | $642K | 64.18 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-12 | Hochman Rodney F | Director | 1,618 | $100K | 62.03 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-08 | Yang Watkin Phoebe L. | Director | 1,000 | $63K | 63.01 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-06 | Culp H Lawrence Jr | Director | 80,805 | $5.0M | 61.88 | Too little history (no open-market trades in 2024 or 2025) |
| 2026-05-06 | Stromberg William J | Director | 1,000 | $62K | 61.69 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-01 | Saccaro James | Chief Financial Officer | 3,310 | $201K | 60.6 | Too little history (no open-market trades in 2023–2025) |
| 2026-04-30 | Jimenez Frank R | GC & Corporate Secretary | 1,750 | $106K | 60.45 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-04-30 | Arduini Peter J | President and CEO | 4,169 | $250K | 59.92 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (GEHC)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | BTIG | Target lowered | Buy | $79 → $75 |
| 2026-10-07 | Barclays | Initiated | Overweight | $85 |
| 2026-10-05 | Citigroup | Target lowered | Neutral | $75 → $71 |
| 2026-10-05 | Needham | Reiterated | Buy | $93 |
| 2026-09-22 | Needham | Initiated | Buy | $93 |
| 2026-09-17 | BTIG | Reiterated | Buy | $79 |
| 2026-08-19 | BTIG | Reiterated | Buy | $79 |
| 2026-07-31 | UBS | Target raised | Neutral | $67 → $73 |
| 2026-07-30 | Citigroup | Target raised | Neutral | $69 → $75 |
| 2026-07-30 | Evercore ISI Group | Target raised | Outperform | $80 → $84 |
| 2026-07-30 | Wells Fargo | Target raised | Overweight | $75 → $85 |
| 2026-07-29 | BTIG | Target raised | Buy | $75 → $79 |
Total return (dividends reinvested) (GEHC)
| 1Y (from 2025-10-23) | 5Y (from 2022-12-12) | |
|---|---|---|
| Total return | -7.4% | +26.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -7.4% | +6.3% |
| Volatility (annualized) | 34.9% | 32.0% |
| Max drawdown | -32.5% (Jan 2026→Apr 2026) | -35.4% (Mar 2024→Mar 2025) |
GEHC revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| AIS | $3.77B | 71.2% | +8.0% |
| PDx | $843.0M | 15.9% | +15.6% |
| PCS | $675.0M | 12.7% | -13.2% |
| Total revenue | $5.29B | 100% | — |
GEHC revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product | $3.42B | 64.5% | +4.7% |
| Service | $1.88B | 35.5% | +7.7% |
| Total revenue | $5.29B | 100% | — |
GEHC revenue by region (fiscal year ended Dec 31, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Other Countries | $9.43B | 45.7% | +5.7% |
| UNITED STATES | $9.17B | 44.5% | +6.4% |
| China | $2.03B | 9.8% | -4.9% |
| Total revenue | $20.63B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
GEHC suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Competitor | Siemens | “In the industries we serve, we believe our primary global competitors include Siemens Healthineers, Philips Healthcare, United Imaging, Mindray, and Canon, among others.” |
Quoted from the company's 10-K filed Feb 4, 2026.
GEHC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.20 | $1.24 | -3.2% | $5.35B | 18 |
| Next quarter (ends Dec 2026) | $1.59 | $1.61 | -1.5% | $5.94B | 16 |
| Current fiscal year (ends Dec 2026) | $4.92 | $4.87 | +1.1% | $21.72B | 22 |
| Next fiscal year (ends Dec 2027) | $5.41 | $5.36 | +0.9% | $22.73B | 22 |
GEHC options: expected move
Options price a move of about ±7.1% (±$5.05) by Oct 30, 2026, which includes earnings on Oct 28, 2026. Over the last 8 reports the stock moved ±6% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 7 | 59.9% | ±7.1% |
| Nov 6, 2026 | 14 | 47.9% | ±7.7% |
| Nov 13, 2026 | 21 | 38.5% | ±7.5% |
| Nov 20, 2026 | 28 | 37.1% | ±8.3% |
| Nov 27, 2026 | 35 | 34.3% | ±8.6% |
| Dec 4, 2026 | 42 | 35.2% | ±9.6% |
| Dec 18, 2026 | 56 | 40.1% | ±12.7% |
| Jan 15, 2027 | 84 | 32.8% | ±12.7% |
30-day implied volatility 39.5% vs 23.4% realized over the last 30 trading days. Put/call ratio (volume) 0.16. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:21 UTC)
| Price | USD 71.42 |
|---|---|
| Change | ▲ 3.49% (up) |
| Previous Close | USD 71.42 |
| Open | USD 71.42 |
| Day Range | USD 69.31 – 71.7 |
| 52-Week Range | USD 58.75 – 89.77 |
| Volume | 3,131,579 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (GEHC)
Nexqual's technical model rates GEHC "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:21 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 62.96 (neutral) |
| vs SMA50 | Above (USD 68.41) |
| MACD | 0.95 (positive) |
Earnings (GEHC)
| Next Earnings Date | 2026-10-28 |
|---|---|
| EPS Estimate | USD 1.2 |
| Revenue Estimate | $5.35B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.13 vs est 1.04 ▲ beat |
| 2026-03-31 | USD 0.99 vs est 1.05 ▼ miss |
| 2025-12-31 | USD 1.44 vs est 1.4 ▲ beat |
| 2025-09-30 | USD 1.07 vs est 1.05 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Financials & Fundamentals (GEHC)
| Total Revenue | $21.27B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +5.80% |
| Gross Margin | +39.53% |
| Operating Margin | +14.98% |
| Profit Margin | +9.33% |
| ROE | +19.38% |
| Debt / Equity | 0.94 |
| Current Ratio | 1.26 |
| Total Cash | $2.08B |
| Total Debt | $10.54B |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Ownership (GEHC)
| Insider Ownership | +0.37% |
|---|---|
| Institutional Ownership | +94.24% |
| Shares Outstanding | 451.69M |
| Float | 450.20M |
| Short % of Float | +4.65% |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Leadership (GEHC)
GE HealthCare Technologies Inc. is led by Peter J. Arduini, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:21 UTC.
| President, CEO & Director | Peter J. Arduini |
|---|---|
| President & CEO of Patient Care Solutions | Jeannette Bankes |
| Chief Financial Officer | William K. Grogan |
Major Backers & Investors (GEHC)
Notable institutional backers of GE HealthCare Technologies Inc. include Dodge & Cox Inc., Invesco, Harris Associates L.P., according to Nexqual as of October 23, 2026 at 09:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 8.38% |
| Invesco | 4.05% |
| Harris Associates L.P. | 3.39% |
| Barrow, Hanley Mewhinney & Strauss, LLC | 2.98% |
| Hotchkis & Wiley Capital Management, LLC | 2.71% |
| Fidelity | 1.31% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.07% |
| BlackRock | 8.3% |
| State Street | 4.62% |
| Geode Capital | 2.85% |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
From GE HealthCare Technologies Inc.'s Latest SEC 10-K Filing (filed 2026-02-04)
Key Strengths & Strategy (as disclosed to the SEC)
- While there have been some recent enforcement actions by EU country-level data protection authorities resulting in substantial fines pursuant to GDPR, there remains uncertainty as to how data protection authorities throughout the rest of the globe will choose to interpret and enforce violations of applicable privacy laws and regulations (e.g., Brazil LGPD, China PIPL).
- We rely on confidentiality agreements with colleagues, contractors, consultants, and third parties to help protect our trade secrets, proprietary technology, and other confidential information.
- We complement our direct and indirect sales channels with end-to-end virtual sales teams.
- Our broad enterprise solutions used along the imaging continuum enable us to drive connectivity across healthcare systems and throughout the product lifecycle.
Partnerships
- We occasionally enter into agreements with third parties related to collaboration on R&D activities associated with the development of new or innovative products.
- In developed markets, we supplement our commercial model with strategic account executive and collaboration teams that bring the depth and breadth of our overall portfolio to the senior leadership of our top customers to deliver long-term commercial collaborations, which can be tied to specific outcomes.
Legal & Regulatory Risks (Item 1A, quoted)
- We are subject to laws and regulations in many jurisdictions governing government contracts, public procurement, and government reimbursements, as to which the failure to comply could adversely affect our business.
- We are exposed to risks associated with potential litigation, arbitration, and governmental proceedings, including product liability claims that have been and may be brought against us.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DXCM | DexCom, Inc. | USD 78.32 | ▼ 2.42% |
| PHG | Koninklijke Philips N.V. NY Reg | USD 26.92 | ▲ 2.63% |
| STE | STERIS plc (Ireland) | USD 232.22 | ▲ 4.85% |
| EW | Edwards Lifesciences Corporatio | USD 90.09 | ▲ 1.91% |
| ZBH | Zimmer Biomet Holdings, Inc. | USD 98.81 | ▲ 4.16% |
| BSX | Boston Scientific Corporation | USD 46.01 | ▲ 3.37% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt